<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00928317</url>
  </required_header>
  <id_info>
    <org_study_id>ART621-221</org_study_id>
    <nct_id>NCT00928317</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate</brief_title>
  <official_title>Multi-Centre Randomised Double-Blind Pbo-Controlled Dose-Ranging Study to Evaluate the Safety, Tolerability, Efficacy, PK and Immunogenicity of Multiple Doses of ART621 for 3 Months in Patients With Rheumatoid Arthritis Taking Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arana Therapeutics Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arana Therapeutics Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to assess the safety, efficacy, tolerability,&#xD;
      immunogenicity and pharmacokinetics of 3 dose levels of ART621 in the treatment of rheumatoid&#xD;
      arthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite being effective in approximately 60% of subjects, there are limitations to existing&#xD;
      anti-TNF therapies especially in relation to immunogenicity, safety and administration. In&#xD;
      addition, due to their high molecular weight, currently marketed products are largely&#xD;
      confined to the blood stream.&#xD;
&#xD;
      ART621 is an anti-TNF molecule that contains 2 identical domain &quot;antibodies&quot; that have the&#xD;
      binding activity of a full antibody but with a substantially smaller molecular size. The&#xD;
      molecular weight of approximately half that of full size antibodies is predicted to, a) have&#xD;
      improved tissue penetration and, b) to be less immunogenic than full size antibodies.&#xD;
&#xD;
      This clinical trial is designed to assess the safety, efficacy, tolerability, immunogenicity&#xD;
      and pharmacokinetics of ART621 when administered with an intravenous loading dose followed by&#xD;
      subcutaneous administration every week.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Corporate re-prioritization&#xD;
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of ART621 on the signs and symptoms of moderate to severe RA in subjects concomitantly taking methotrexate as assessed by the proportion of subjects achieving an ACR20 response.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-response relationship of ART621 against the signs and symptoms of moderate to severe RA as assessed by additional efficacy, safety and QoL parameters.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity profile of ART621 as assessed by development of HAHAs.</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration versus time profile and population PK of ART621 in subjects with RA.</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of ART621 on immunological parameters and other disease biomarkers.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>ART621 A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ART621 0.75mg/kg per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ART621 B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ART621 1.5 mg/kg per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ART621 C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ART621 3.0mg/kg per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ART621</intervention_name>
    <description>3.0mg/kg s.c.</description>
    <arm_group_label>ART621 C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ART621</intervention_name>
    <description>1.5mg/kg s.c.</description>
    <arm_group_label>ART621 B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ART621</intervention_name>
    <description>0.75mg/kg s.c.</description>
    <arm_group_label>ART621 A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo s.c.</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of a valid written informed consent.&#xD;
&#xD;
          -  Male or female subjects ≥ 18 and ≤ 80 years old.&#xD;
&#xD;
          -  Women of childbearing potential, or men of fathering potential, must be using adequate&#xD;
             (in the investigator's opinion) birth control measures (e.g. abstinence, oral&#xD;
             contraceptives, intrauterine device, barrier method with spermicide, or surgical&#xD;
             sterilisation) during the study. Female subjects of childbearing potential must test&#xD;
             negative for pregnancy prior to enrolling in the study. Post menopausal (cessation of&#xD;
             menses for more than 2 years) women are eligible for this study.&#xD;
&#xD;
          -  Diagnosis of RA according to the revised (1987) American College of Rheumatology&#xD;
             criteria for at least 6 months and no longer than 3 years prior to screening.&#xD;
&#xD;
          -  Meet ACR functional class criteria I, II or III.&#xD;
&#xD;
          -  Have active RA at the time of screening and at baseline, defined as ≥ 6 swollen joints&#xD;
             and ≥ 6 tender joints (from 68 joint count) together with at least 2 of the following&#xD;
             3 criteria:&#xD;
&#xD;
               -  CRP level ≥ 1.5 mg/dl;&#xD;
&#xD;
               -  ESR by Westergren method ≥ 28 mm in the first hour; or&#xD;
&#xD;
               -  morning stiffness ≥ 45 minutes.&#xD;
&#xD;
          -  At least one of the following should be present at screening:&#xD;
&#xD;
               -  documented history or current presence of positive rheumatoid factor;&#xD;
&#xD;
               -  presence of serum anti-CCP antibodies; or&#xD;
&#xD;
               -  screening radiographic erosion&#xD;
&#xD;
          -  Have been tolerating concomitant methotrexate (oral or subcutaneous) for at least 3&#xD;
             months prior to screening and on a stable dose between 10-25 mg per week for at least&#xD;
             6 weeks prior to the first study dose. The route of administration must also be&#xD;
             stable. Use of methotrexate dose of 25-50 mg every 2 weeks is also acceptable. (Other&#xD;
             DMARDs taken concomitantly with methotrexate are not allowed. Those subjects&#xD;
             concomitantly receiving additional DMARDs with methotrexate may enter the study by&#xD;
             stopping the additional DMARD at least 4 weeks prior to first study dose).&#xD;
&#xD;
          -  If using the following medication, the subject must be on a stable dose for the 4&#xD;
             weeks prior to the first study dose and maintain that dose throughout the study:&#xD;
&#xD;
               -  oral corticosteroids, equivalent to ≤ 10 mg of prednisone/day.&#xD;
&#xD;
               -  one nonsteroidal anti-inflammatory drug (NSAID).&#xD;
&#xD;
               -  3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) or fibrates&#xD;
                  (see Section 7.1 for acceptable doses).&#xD;
&#xD;
          -  Does not have active or latent TB according to eligibility assessment and screening&#xD;
             rules (see Section 8.3.1).&#xD;
&#xD;
          -  Is willing and able to comply with study visits and other protocol requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant, nursing, or planning a pregnancy (both men and women) within 9 months of&#xD;
             enrolment.&#xD;
&#xD;
          -  Subjects weighing &gt; 100 kgs.&#xD;
&#xD;
          -  Screening laboratory tests:&#xD;
&#xD;
               -  hemoglobin ≤ 8.0 gm/dl&#xD;
&#xD;
               -  white blood cells ≤ 3.0 x103 cells/µl&#xD;
&#xD;
               -  neutrophils ≤ 1.5 x 103 cells/µl&#xD;
&#xD;
               -  platelets ≤100 x 103 cells/µl&#xD;
&#xD;
               -  serum transaminase level (AST and ALT) ≥ 2 times upper limit of normal (ULN)&#xD;
&#xD;
               -  serum creatinine ≥ 0.15 mmol/l&#xD;
&#xD;
          -  Subjects with diagnosis of juvenile arthritis or other inflammatory or autoimmune&#xD;
             diseases that might confound the evaluations of benefit from ART621 such as ankylosing&#xD;
             spondylitis, systemic lupus erythematosus and Lyme disease.&#xD;
&#xD;
          -  Subjects who have previously failed to respond to any oral or injectable anti-TNFα&#xD;
             therapy or subjects who have had to stop anti-TNFα therapy for safety reasons.&#xD;
             Subjects who have successfully responded to anti-TNFα therapy in the past (but&#xD;
             discontinued for reasons other than safety or lack of efficacy) &gt; 6 months prior to&#xD;
             study day one may enrol. Patients who have participated in a previous anti-TNFα&#xD;
             therapy study are eligible if they are confirmed to have received placebo.&#xD;
&#xD;
          -  Subjects who have previously received the following anti-rheumatic drugs:&#xD;
             interleukin-1 receptor antagonist [anakinra], rituximab, anti-CD4 antibody, abatacept,&#xD;
             thalidomide, p38 MAP kinase inhibitor and other agents (other than those listed in&#xD;
             Section 7.3).&#xD;
&#xD;
          -  Subjects who have undergone plasmapheresis within 6 months prior to randomisation.&#xD;
&#xD;
          -  Have received intraarticular, intramuscular, or intravenous corticosteroids, including&#xD;
             intramuscular adrenocorticotropic hormone, during the 4 weeks prior to the first study&#xD;
             dose, or non-stable doses of oral steroids.&#xD;
&#xD;
          -  Subjects with a history of any clinically significant adverse reaction to murine or&#xD;
             chimeric proteins, including serious allergic reactions.&#xD;
&#xD;
          -  Subjects with Felty's syndrome or a history of Felty's syndrome.&#xD;
&#xD;
          -  Subjects who have received or are expecting to receive any live virus or bacterial&#xD;
             vaccinations within 1 month before first study dose, during the study, or up to 3&#xD;
             months after the study dose.&#xD;
&#xD;
          -  Subjects with a history of, presence of, or at high risk of serious infection&#xD;
             including:&#xD;
&#xD;
               -  history of active TB, or positive Mantoux test or QuantiFERON Gold test or chest&#xD;
                  x-ray suggestive of active or healed TB or positive contact history with a&#xD;
                  subject with active TB within the past 3 months. If subjects have a positive&#xD;
                  Mantoux test but a negative QuantiFERON Gold test, they may be enrolled.&#xD;
&#xD;
               -  a serious infection during the 3 months prior study entry (hospitalised or&#xD;
                  received IV antibiotics for an infection).&#xD;
&#xD;
               -  chronic or recurrent infectious disease.&#xD;
&#xD;
               -  systemic fungal infections&#xD;
&#xD;
               -  opportunistic infection within 3 months prior to screening (refer to 1993 CDC&#xD;
                  Classification System for HIV Infection).&#xD;
&#xD;
               -  subjects known, or suspected, to be infected with HIV, hepatitis B, or hepatitis&#xD;
                  C.&#xD;
&#xD;
               -  subjects with planned joint replacement surgery or a history of infected joint&#xD;
                  prosthesis or who have received antibiotics for a suspected infection of a joint&#xD;
                  prosthesis if that prosthesis has not been removed or replaced.&#xD;
&#xD;
          -  Subjects with a known history of demyelinating diseases such as multiple sclerosis or&#xD;
             optic neuritis.&#xD;
&#xD;
          -  Subjects with evidence of severe, progressive, or uncontrolled renal, hepatic,&#xD;
             hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, psychiatric,&#xD;
             or cerebral disease.&#xD;
&#xD;
          -  Concurrent CHF, including medically controlled, asymptomatic CHF or ECG findings&#xD;
             suggestive of CHF.&#xD;
&#xD;
          -  Subjects receiving cytotoxic drugs including cyclophosphamide, cyclosporine, or&#xD;
             alkylating agents within 6 months prior to first study dose.&#xD;
&#xD;
          -  Known history or evidence of malignancy, lymphoproliferative or neoplastic disease&#xD;
             with the exception of successfully treated basal or squamous cell carcinoma of the&#xD;
             skin or cervical intraepithelial neoplasia.&#xD;
&#xD;
          -  Subjects who have undergone organ transplant (with exception of a corneal transplant&#xD;
             more than 3 months prior to screening).&#xD;
&#xD;
          -  Subjects previously enrolled in this study, currently participating in another&#xD;
             investigational study or treated with any investigational drug within the previous 3&#xD;
             months or within 5 half-lives, whichever is greater, prior to first study dose.&#xD;
&#xD;
          -  Any other clinically significant disease or disorder or factors such as substance&#xD;
             abuse which in the opinion of the investigator make the subject ineligible for&#xD;
             participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tampa Medical Group P.A.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physician Research Collaboration, LLC</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westroads Medical Group</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Northwest, PLLC</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Clinic</name>
      <address>
        <city>Racine</city>
        <state>Wisconsin</state>
        <zip>53142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Medico Especializado IME</name>
      <address>
        <city>Buenos Aires</city>
        <state>BUE</state>
        <zip>C1405BCH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Medico CER</name>
      <address>
        <city>Quilmes</city>
        <state>Bue</state>
        <zip>B1878DVB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ILAIM-CEOM Inst. Latinoamericano de Inv. Medicas</name>
      <address>
        <city>Cordoba</city>
        <state>CRD</state>
        <zip>X5000BNB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Parque S.A.</name>
      <address>
        <city>Rosario</city>
        <state>SFE</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAICI</name>
      <address>
        <city>Rosario</city>
        <state>SFE</state>
        <zip>S2000PBJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ctro Polivalente de Asist e Invest Clinica CER</name>
      <address>
        <city>San Juan</city>
        <state>SJN</state>
        <zip>5400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Privado de Reumatologia</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>TUC</state>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Reumatológicas</name>
      <address>
        <city>Tucuman</city>
        <state>TUC</state>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMAI Research - Instituto Medico de Asistencia y Investigaci</name>
      <address>
        <city>Calle French</city>
        <zip>2673</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Privado de Reumatologia</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyell McEwin Hospital</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>New South Wales</state>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown Arthritis Centre</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coast Joint Care</name>
      <address>
        <city>Maroochydore</city>
        <state>Queensland</state>
        <zip>4558</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicka ambulance</name>
      <address>
        <city>Bruntal</city>
        <zip>79201</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Jihlava</name>
      <address>
        <city>Jihlava</city>
        <zip>58633</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARTHROMED s. r. o.</name>
      <address>
        <city>Pardubice</city>
        <zip>53002</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Plzen</name>
      <address>
        <city>Plzen - Bory</city>
        <zip>30599</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicky ustav</name>
      <address>
        <city>Praha 2</city>
        <zip>12850</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospital Educational and Research Foundation</name>
      <address>
        <city>Hyderabaad</city>
        <state>Andh Prad</state>
        <zip>500033</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizams Institute of Medical Sciences</name>
      <address>
        <city>Hyderabaad</city>
        <state>Andh Prad</state>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krishna Institute of Medical Sciences</name>
      <address>
        <city>Secunderabad</city>
        <state>Andh Prad</state>
        <zip>500003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King George Hospital</name>
      <address>
        <city>Vishakhapattanam</city>
        <state>Andh Prad</state>
        <zip>530002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Medical College Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karna</state>
        <zip>560034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.S. Ramaiah Memorial Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karna</state>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Rheumatic Diseases</name>
      <address>
        <city>Pune</city>
        <state>Mahara</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospitals Educational and Research Foundation</name>
      <address>
        <city>Madurai</city>
        <state>Tamilnadu</state>
        <zip>625020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanjay Gandhi Postgraduate Institute</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Prad</state>
        <zip>226014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. M. C. Hospital</name>
      <address>
        <city>Mangalore</city>
        <zip>575001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Putra Medical Centre</name>
      <address>
        <city>Alor Setar</city>
        <state>Kedah</state>
        <zip>05100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50480</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ipoh</name>
      <address>
        <city>Perak</city>
        <zip>30990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarawak General Hospital</name>
      <address>
        <city>Sarawak</city>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C G M Research Trust, The Princess Margaret Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8002</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Osteoporozy i Chorob Kostno-Stawowych</name>
      <address>
        <city>Bialystok</city>
        <zip>15-461</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny ZOZ w Dzialdowie</name>
      <address>
        <city>Dzialdowo</city>
        <zip>13-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nzoz Reumed</name>
      <address>
        <city>Lublin</city>
        <zip>20-607</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medyczne Centrum Hetmanska</name>
      <address>
        <city>Poznan</city>
        <zip>60-218</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPSK nr 1 im. Tadeusza Sokolowskiego PAM</name>
      <address>
        <city>Szczecin</city>
        <zip>71-252</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne OSTEOMED</name>
      <address>
        <city>Warszawa</city>
        <zip>02-341</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Czech Republic</country>
    <country>India</country>
    <country>Malaysia</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>June 24, 2009</study_first_submitted>
  <study_first_submitted_qc>June 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <last_update_submitted>January 4, 2010</last_update_submitted>
  <last_update_submitted_qc>January 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>David Fuller, Chief Medical Officer</name_title>
    <organization>Arana Therapeutics Limited</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

